Avalon GloboCare (ALBT) has shared an announcement.
Avalon GloboCare Corp. has announced the launch of a groundbreaking non-invasive DNA test available directly to consumers in the U.S., designed to identify individual predispositions to opioid dependence. This innovative test represents a significant step forward in personalized healthcare and the fight against the opioid crisis.
For an in-depth examination of ALBT stock, go to TipRanks’ Stock Analysis page.
